{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715832,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.253","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T02:40:35Z","timestamp":1502678435000},"page":"2398-2406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":298,"title":["Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants"],"prefix":"10.1038","volume":"31","author":[{"name":"for the SAKK and the German CML Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lauseker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D K","family":"Hossfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Nerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gratwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G M","family":"Baerlocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Proetel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kohlbrenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Voskanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Rinaldetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Seifarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Spie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Balleisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Falge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kneba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"K\u00f6hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H W","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C F","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D W","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wernli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Thomalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Gassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bildat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"BFleu2017253_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"S O'Brien","year":"2003","unstructured":"O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2017253_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376: 917\u2013927.","journal-title":"N Engl J Med"},{"key":"BFleu2017253_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller MC, Pletsch N et al. Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu2017253_CR4","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096\u20132102.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015; 126: 42\u201349.","journal-title":"Blood"},{"key":"BFleu2017253_CR6","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760\u20136768.","journal-title":"Blood"},{"key":"BFleu2017253_CR7","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","volume":"94","author":"A Fabarius","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015; 94: 2015\u20132024.","journal-title":"Ann Hematol"},{"key":"BFleu2017253_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu2017253_CR9","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511\u20132521.","journal-title":"N Engl J Med"},{"key":"BFleu2017253_CR10","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228\u20133235.","journal-title":"Blood"},{"key":"BFleu2017253_CR11","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009; 113: 4497\u20134504.","journal-title":"Blood"},{"key":"BFleu2017253_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu2017253_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","volume":"99","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014; 99: 616\u2013624.","journal-title":"Int J Hematol"},{"key":"BFleu2017253_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bjh.12618","volume":"164","author":"MW Deininger","year":"2014","unstructured":"Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E et al. Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014; 164: 223\u2013232.","journal-title":"Br J Haematol"},{"key":"BFleu2017253_CR15","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600mg\/day of imatinib as initial therapy. Blood 2008; 112: 3965\u20133973.","journal-title":"Blood"},{"key":"BFleu2017253_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125: 915\u2013923.","journal-title":"Blood"},{"key":"BFleu2017253_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C et al. Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34: 2333\u20132340.","journal-title":"J Clin Oncol"},{"key":"BFleu2017253_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044\u20131054.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/leu.2015.281","volume":"30","author":"A Gratwohl","year":"2016","unstructured":"Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016; 30: 562\u2013569.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809\u20131820.","journal-title":"Blood"},{"key":"BFleu2017253_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2017253_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850\u2013858.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2017253_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48\u201356.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR24","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR25","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NCP, M\u00fcller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2017253_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208\u20131215.","journal-title":"Blood"},{"key":"BFleu2017253_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0197-2456(97)00074-3","volume":"18","author":"WD Dupont","year":"1997","unstructured":"Dupont WD . PS power and sample size program available for free on the internet. Controlled Clin Trial 1997; 18: 274.","journal-title":"Controlled Clin Trial"},{"key":"BFleu2017253_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","volume":"38","author":"DA Schoenfeld","year":"1982","unstructured":"Schoenfeld DA, Richter JR . Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163\u2013170.","journal-title":"Biometrics"},{"key":"BFleu2017253_CR29","unstructured":"Shkolnikov V, Barbieri M, Wilmoth J . The Human Mortality Database http:\/\/www.mortality.org\/ ."},{"key":"BFleu2017253_CR30","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1007\/s00277-015-2316-0","volume":"94","author":"M Pfirrmann","year":"2015","unstructured":"Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J . Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 2015; 94: S209\u2013S218.","journal-title":"Ann Hematol"},{"key":"BFleu2017253_CR31","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J . Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433\u20131438.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2017253_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710\u2013719.","journal-title":"J Clin Oncol"},{"key":"BFleu2017253_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cmpb.2006.01.004","volume":"81","author":"M Pohar","year":"2006","unstructured":"Pohar M, Stare J . Relative survival analysis in R. Comput Methods Programs Biomed 2006; 81: 272\u2013278.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFleu2017253_CR35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFleu2017253_CR36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2017253_CR37","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","volume":"140","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014; 140: 1965\u20131969.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFleu2017253_CR38","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFleu2017253_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17: 612\u2013621.","journal-title":"Lancet Oncol"},{"key":"BFleu2017253_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017253","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:09:05Z","timestamp":1684418945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu2017253"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.253","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"assertion":[{"value":"23 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RH received research support from Novartis and honoraria from BMS, SS research support from Novartis, BMS, Ariad and Pfizer, MP honoraria from Novartis and BMS, SK honoraria from Novartis, GMB honoraria from Novartis, BMS and Pfizer, THB research support from Novartis, MCM grants and honoraria from Novartis, BMS, Ariad and Pfizer, AB honoraria from BMS, JM research support from Novartis and BMS, HL honoraria from Novartis, PS honoraria from Novartis, BMS, Pfizer and Ariad, CS honoraria from Novartis, AH research support from Novartis and honoraria from Novartis, BMS and Pfizer; all other authors reported no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}